Suppr超能文献

肿瘤浸润性FOXP3 + T细胞密度作为诱导放化疗的反应标志物及局部晚期非小细胞肺癌三联疗法治疗患者的潜在预后因素。

Density of tumor-infiltrating FOXP3+ T cells as a response marker for induction chemoradiotherapy and a potential prognostic factor in patients treated with trimodality therapy for locally advanced non-small cell lung cancer.

作者信息

Tao Hiroyuki, Shien Kazuhiko, Soh Junichi, Matsuda Eisuke, Toyooka Shinichi, Okabe Kazunori, Miyoshi Shinichiro

机构信息

Division of Thoracic Surgery, NHO Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan.

出版信息

Ann Thorac Cardiovasc Surg. 2014;20(6):980-6. doi: 10.5761/atcs.oa.13-00237. Epub 2014 Feb 28.

Abstract

PURPOSE

To examine the relationship between the density of tumor-infiltrating T cell subpopulations and the pathological response to induction chemoradiotherapy (CRT) in patients with locally advanced NSCLC, and to assess the impact of T cell density on patient prognosis.

METHODS

A total of 64 patients with c-stages IIA-IIIB NSCLC who underwent induction CRT followed by R0 surgery were enrolled. Tumor-infiltrating T cells expressing either FOXP3 or CD8 were detected by immunohistochemical staining.

RESULTS

Mean numbers of tumor-infiltrating FOXP3+ T cells were 39.9 for patients with minor pathological responses (n = 9), 18.4 for those with major pathological responses (n = 25), and 12.9 for those with complete pathological responses (n = 30; P <0.001). The number of CD8+ T cells was not associated with pathological responses. Patients with lower FOXP3+ T cell densities showed better survival, although the difference was not statistically significant.

CONCLUSION

Our study demonstrated that the density of tumor-infiltrating FOXP3+ T cells indicated the degree of response for induction CRT and prognosis in patients treated with trimodality therapy for locally advanced NSCLC, suggesting that FOXP3+ T cells may be target for adjunct immunotherapy.

摘要

目的

探讨局部晚期非小细胞肺癌(NSCLC)患者肿瘤浸润性T细胞亚群密度与诱导放化疗(CRT)病理反应之间的关系,并评估T细胞密度对患者预后的影响。

方法

共纳入64例c期IIA-IIIB期NSCLC患者,这些患者先接受诱导CRT,然后接受R0手术。通过免疫组织化学染色检测表达FOXP3或CD8的肿瘤浸润性T细胞。

结果

病理反应轻微的患者(n = 9)肿瘤浸润性FOXP3 + T细胞的平均数量为39.9,病理反应主要的患者(n = 25)为18.4,病理反应完全的患者(n = 30)为12.9;P <0.001。CD8 + T细胞数量与病理反应无关。FOXP3 + T细胞密度较低的患者生存率较好,尽管差异无统计学意义。

结论

我们的研究表明,肿瘤浸润性FOXP3 + T细胞密度表明局部晚期NSCLC接受三联疗法治疗患者的诱导CRT反应程度和预后,提示FOXP3 + T细胞可能是辅助免疫治疗的靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验